Bifido Obtains Patent Rights for Composition Related to Rheumatoid Arthritis Improvement
[Asia Economy Reporter Minji Lee] Bifido announced on the 7th that it has obtained a patent in Korea for the Bifidobacterium pseudocatenulatum C-RAPO strain and compositions containing it, aimed at improving, preventing, or treating rheumatoid arthritis.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Hancom Breaks Away from Its 36-Year Mission and Formula for Success" (Comprehensive)
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "The Bifidobacterium pseudocatenulatum C-RAPO strain has shown efficacy in preventing or treating rheumatoid arthritis, confirming that it delays symptom scores, onset timing, and significantly reduces the incidence of rheumatoid arthritis," adding, "We will utilize it in clinical research for the development of rheumatoid arthritis treatments in consultation with the Ministry of Food and Drug Safety."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
